Liquid Biopsy Technologies Hasten Progress in Precision Oncology genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
The FDA companion diagnostic designation for FoundationOne CDx may improve access to niraparib/abiraterone acetate for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) harboring a BRCA mutation.
The global liquid biopsy market was estimated at USD 4,722.73 million in 2022 and is anticipated to hit around USD 18,280.13 million by 2032, registering a.
The companies will develop FoundationOne Liquid CDx and FoundationOne CDx as CDx tests in the US market for selected Merck KGaA marketed and pipeline treatments.
The combination of panitumumab and standard-of-care trifluridine-tipiracil rechallenge delivered a progression-free survival benefit vs trifluridine-tipiracil alone in the third-line setting in patients with refractory RAS wild-type metastatic colorectal cancer, meeting the primary end point of the phase 2 VELO trial.